Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
prnewswire.com
news
2022-10-19 10:00:00

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and JapanÂ Zymeworks to receive $50 million upfront payment, a second payment of $325 million, at Jazz's option, and further potential regulatory and commercial milestones for total potential payments of up to $1.76 billion, plus royalties on net salesJazz continues to expand oncology portfolio with novel late-stage asset with compelling anti-tumor activityTop-line clinical data for zanidatamab in biliary tract cancer (HERIZON-BTC-01) expected by end of 2022; potential to support first global regulatory filingsDUBLIN and VANCOUVER, Oct.
